Monoacylglycerol Lipase (MAGL) is a serine hydrolase that is essential in catalyzing the hydrolysis of monoglycerides into glycerol and fatty acids. By converting the plentiful endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators, MAGL connects the endocannabinoid and eicosanoid systems.
MAGL is a key enzyme that regulates the levels of 2-AG, an important lipid with a variety of neuroprotective effects; ii) when MAGL is inactive, 2-AG levels in the brain are elevated and AA levels are decreased, which reduces the production of pro-inflammatory prostaglandins, which reduces neuroinflammation; and iii) MAGL controls the levels of free fatty acids (FFAs) in aggressive cancer cells, and this MAGL-promote MAGL is becoming a potentially effective drug target for a number of diseases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73516 | 7-Hydroxycoumarinyl arachidonate (7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate) | 161180-11-6 | 7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorescent substrate for cytosolic phospholipase A2 (PLA2) and monoacylglycerol lipase (MAGL). |
|
V71791 | AA38-3 | 65815-76-1 | AA38-3 is a serine hydrolase (SH) inhibitor. |
|
V73513 | ABC34 | 1831135-56-8 | ABC34 is the inactive control compound of JJH260. |
|
V77308 | ABD957 | ABD957 is a potent and specific covalent inhibitor of the ABHD17 family of depalmitoylases with an inhibition IC50 of 0.21 µM. | |
|
V3834 | ABX-1431 | 1446817-84-0 | ABX-1431 is a highly potent, selective, covalent, irreversible, and orally bioavailable, CNS-penetrant MGLL (serine hydrolase monoacylglycerol lipase) inhibitor that has potential use in the treatment of neurological disorders. |
|
V73519 | Arachidonoyl Serinol | 183718-70-9 | Arachidonoyl Serinol, an endogenously produced metabolite of cannabinoids, is an inhibitor (blocker/antagonist) of monoacylglycerol lipase (MAGL). |
|
V71795 | FAAH/MAGL-IN-2 | 2765077-82-3 | FAAH/MAGL-IN-2 is a potent, reversible, orally bioactive and BBB (blood-brain barrier) permeable (penetrable) inhibitor of FAAH and MAGL with IC50s of 11 nM and 36 nM respectively (b>Kis of 28 nM and 60 nM). |
|
V71794 | FAAH/MAGL-IN-3 | 2848719-34-4 | FAAH/MAGL-IN-3 (Compound 10) is an irreversible dual (bifunctional) inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with IC50s of 179 and 759 nM for FAAH and MAGL, respectively. |
|
V67634 | JJH260 | 1831135-30-8 | JJH260 is an AIG1 inhibitor that can suppress the fluorophosphonate reactivity and FAHFA hydrolytic activity of AIG1 in HEK293T cells with IC50s of 0.50 and 0.57 μM, respectively. |
|
V1949 | JZL184 | 1101854-58-3 | JZL 184 is the first potent, irreversible and selective inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 8 NM. |
|
V73520 | JZP-MA-11 | 1672691-50-7 | JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid alpha/beta-hydrolase domain 6 (ABHD6) enzyme. |
|
V80207 | JZP-MA-13 | JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor (antagonist) with IC50 of 392 nM. | |
|
V12562 | KML-29 | 1380424-42-9 | KML-29 is monoacylglycerol lipase inhibitor and an O-hexafluoroisopropyl carbamate analogue of JZL 184. |
|
V73514 | MAGL-IN-1 | 2324160-91-8 | MAGL-IN-1 is a specific, reversible and competitive MAGL inhibitor (antagonist) with IC50 of 80 nM. |
|
V79016 | MAGL-IN-10 | MAGL-IN-10 is a reversible monoacylglycerol lipase (MAGL) inhibitor (antagonist) with very good ADME properties and low in vivo toxicity. | |
|
V80663 | MAGL-IN-11 | MAGL-IN-11 (compound 29) is a selective and reversible MAGL inhibitor. | |
|
V73515 | MAGL-IN-4 | 2135785-20-3 | MAGL-IN-4 is an orally bioactive, selective and reversible inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 6.2 nM. |
|
V78909 | MAGL-IN-8 | MAGL-IN-8 (compound 13) is a reversible inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 2.5 ± 0.4 nM for hMAGL. | |
|
V79017 | MAGL-IN-9 | MAGL-IN-9 (compound 16) is a selective, reversible inhibitor of MAGL with IC50 of 2.7 nM. | |
|
V73517 | ML-211 | 2205032-89-7 | ML-211 is a dual carbamate-based inhibitor of acyl protein thioesterase 1 (APT1)/lysophospholipase 1 (LYPLA1) (IC50=17 nM) and LYPLA2 (IC50=30 nM). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
